Caplacizumab
- PDF / 168,852 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 163 Views
1 S
Vaginal haemorrhages: case report In an observational, retrospective analysis of 60 patients, conducted in 29 medical centres in Germany between June 2018 and December 2019, a woman [age not stated] was described, who developed recurrent vaginal haemorrhages 2 weeks after delivery during treatment with caplacizumab for acquired thrombotic thrombocytopenic purpura [dosage, route, duration of treatment to reaction onset and outcome not stated]. Therefore, caplacizumab treatment was initially paused and then discontinued. Volker LA, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Advances 4: 3085-3092, No. 13, 14 Jul 803499229 2020. Available from: URL: http://doi.org/10.1182/bloodadvances.2020001973
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
